Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Palma

Showing results (201-210 of 227) with videos related to

Pageof 23
Sort By:
Molecular Imaging and Biology|December 15, 2011
Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft modelSarah R Mudd, Kimberley D Holich, Martin J Voorbach, et al.
Jornal Brasileiro De Nefrologia|September 3, 2020
Recommendations from the Brazilian Society of Nephrology for approaching Covid-19 Diagnostic Testing in Dialysis UnitsJosé A Moura-Neto, Lilian M P Palma, Gabriel F Marchiori, et al.
The Pharmacogenomics Journal|February 4, 2009
Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152J Guo, M G Anderson, P Tapang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft modelsDebra Ferguson, Luis E Rodriguez, Joann P Palma, et al.
Molecular Cancer Therapeutics|August 28, 2020
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug ConjugateMark G Anderson, Hugh D Falls, Michael J Mitten, et al.
Pharmacology|July 26, 2017
A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor ReceptorKedar S Vaidya, Anatol Oleksijew, Lora A Tucker, et al.
Kidney International|March 6, 2024
Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathyBenjamin Madden, Raman Deep Singh, Mark Haas, et al.
Cancer Research|October 28, 2025
ABBV-303 is a Natural Killer Cell Engager Specific for c-Met-Expressing TumorsJennifer D Stone, Kamonwan Fish, Devika Ashok, et al.
Pediatric Surgery International|August 16, 2023
Long-term urological outcome of cloaca patients with multidisciplinary managementC Pellegrino, M Agamennone, B D Iacobelli, et al.
Molecular Cancer Therapeutics|June 9, 2023
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic MalignanciesAdam S Chervin, Jennifer D Stone, Iwona Konieczna, et al.
Pageof 23

Showing results (201-210 of 227) with videos related to

Sort By:
Pageof 23
Molecular Imaging and Biology|December 15, 2011
Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft modelSarah R Mudd, Kimberley D Holich, Martin J Voorbach, et al.
Jornal Brasileiro De Nefrologia|September 3, 2020
Recommendations from the Brazilian Society of Nephrology for approaching Covid-19 Diagnostic Testing in Dialysis UnitsJosé A Moura-Neto, Lilian M P Palma, Gabriel F Marchiori, et al.
The Pharmacogenomics Journal|February 4, 2009
Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152J Guo, M G Anderson, P Tapang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft modelsDebra Ferguson, Luis E Rodriguez, Joann P Palma, et al.
Molecular Cancer Therapeutics|August 28, 2020
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug ConjugateMark G Anderson, Hugh D Falls, Michael J Mitten, et al.
Pharmacology|July 26, 2017
A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor ReceptorKedar S Vaidya, Anatol Oleksijew, Lora A Tucker, et al.
Kidney International|March 6, 2024
Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathyBenjamin Madden, Raman Deep Singh, Mark Haas, et al.
Cancer Research|October 28, 2025
ABBV-303 is a Natural Killer Cell Engager Specific for c-Met-Expressing TumorsJennifer D Stone, Kamonwan Fish, Devika Ashok, et al.
Pediatric Surgery International|August 16, 2023
Long-term urological outcome of cloaca patients with multidisciplinary managementC Pellegrino, M Agamennone, B D Iacobelli, et al.
Molecular Cancer Therapeutics|June 9, 2023
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic MalignanciesAdam S Chervin, Jennifer D Stone, Iwona Konieczna, et al.
Pageof 23